F
Fleur Weeber
Researcher at Netherlands Cancer Institute
Publications - 17
Citations - 3629
Fleur Weeber is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Organoid & Cancer. The author has an hindex of 11, co-authored 17 publications receiving 2184 citations.
Papers
More filters
Journal ArticleDOI
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
Norman Sachs,Joep de Ligt,Oded Kopper,Ewa Gogola,Gergana Bounova,Fleur Weeber,Anjali Vanita Balgobind,Karin Wind,Ana Gracanin,Harry Begthel,Jeroen Korving,Ruben van Boxtel,Alexandra A. Duarte,Daphne Lelieveld,Arne Van Hoeck,Robert F Ernst,Francis Blokzijl,Isaac J. Nijman,Marlous Hoogstraat,Marieke van der Ven,David A. Egan,Vittoria Zinzalla,Jürgen Moll,Sylvia F. Boj,Emile E. Voest,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Paul J. van Diest,Sven Rottenberg,Sven Rottenberg,Robert G.J. Vries,Edwin Cuppen,Hans Clevers +32 more
TL;DR: This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.
Journal ArticleDOI
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Krijn K. Dijkstra,Chiara M Cattaneo,Fleur Weeber,Myriam Chalabi,Joris van de Haar,Lorenzo F. Fanchi,Maarten Slagter,Daphne L. van der Velden,Sovann Kaing,Sander Kelderman,Nienke van Rooij,Monique E. van Leerdam,Annekatrien Depla,Egbert F. Smit,Koen J. Hartemink,Rosa de Groot,Monika C. Wolkers,Norman Sachs,Petur Snaebjornsson,Kim Monkhorst,John B. A. G. Haanen,Hans Clevers,Ton N. Schumacher,Emile E. Voest +23 more
TL;DR: A platform to induce and analyze tumor-specific T cell responses to epithelial cancers in a personalized manner is established and co-cultures of autologous tumor organoids and peripheral blood lymphocytes can be used to enrich tumor-reactive T cells from peripheral blood of patients with mismatch repair-deficient colorectal cancer and non-small-cell lung cancer.
Journal ArticleDOI
Long-term expanding human airway organoids for disease modeling
Norman Sachs,Angelos Papaspyropoulos,Domenique D. Zomer-van Ommen,Inha Heo,Lena Böttinger,Dymph Klay,Fleur Weeber,Guizela Huelsz-Prince,Nino Iakobachvili,Gimano D. Amatngalim,Joep de Ligt,Arne Van Hoeck,Natalie Proost,Marco C. Viveen,Anna Lyubimova,Luc Teeven,Sepideh Derakhshan,Jeroen Korving,Harry Begthel,Johanna F. Dekkers,Kuldeep Kumawat,Emilio Ramos,Matthijs F.M. van Oosterhout,G. Johan A. Offerhaus,Dominique J Wiener,Eduardo P. Olimpio,Krijn K. Dijkstra,Egbert F. Smit,Maarten van der Linden,Sridevi Jaksani,Marieke van de Ven,Jos Jonkers,Anne C. Rios,Emile E. Voest,Coline H.M. van Moorsel,Cornelis K. van der Ent,Edwin Cuppen,Alexander van Oudenaarden,Frank E. J. Coenjaerts,Linde Meyaard,Louis Bont,Peter J. Peters,Sander J. Tans,Jeroen S. van Zon,Sylvia F. Boj,Robert G.J. Vries,Jeffrey M. Beekman,Hans Clevers +47 more
TL;DR: It is concluded that human airway organoids represent versatile models for the in vitro study of hereditary, malignant, and infectious pulmonary disease.
Journal ArticleDOI
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Salo N. Ooft,Fleur Weeber,Krijn K. Dijkstra,Chelsea M. McLean,Sovann Kaing,Erik van Werkhoven,Luuk J. Schipper,L.R. Hoes,Daniel J. Vis,Joris van de Haar,Warner Prevoo,Petur Snaebjornsson,Daphne L. van der Velden,Michelle Klein,Myriam Chalabi,Henk Boot,Monique E. van Leerdam,Haiko J. Bloemendal,Laurens V. Beerepoot,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Edwin Cuppen,Hans Clevers,Emile E. Voest +23 more
TL;DR: An in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC) is developed and the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy is shown.
Journal ArticleDOI
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
TL;DR: This review highlights what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development.